A new low-cost diagnostic test for coronavirus disease 2019 (COVID-19) quickly delivers accurate results without the need for sophisticated equipment, according to a study published August 27 2020 in the open-access journal PLOS Pathogens by Teng Xu of the Vision Medicals Center for Infectious Diseases, Tieying Hou of the Guangdong Academy of Medical Sciences, Bing Gu of the Affiliated Hospital of Xuzhou Medical University, Jianwei Wang of the Chinese Academy of Medical Sciences and Peking Union Medical College, and colleagues.
The surging demand for rapid screening and identification of COVID-19 poses great diagnostic challenges. Metagenomic next-generation sequencing (mNGS) and reverse-transcription PCR (RT-PCR) have been the most commonly used molecular methods for diagnosing COVID-19, but each has its own limitations. For example, sequencing is costly and has a turnaround time of nearly one day, while RT-PCR requires specialized equipment and is difficult to deploy at a large scale. A lack of rapid and accurate molecular diagnostic tools has hampered efficient public health responses to the viral threat.
In the new study, the researchers developed an alternative COVID-19 test by leveraging CRISPR-based technology, which has been widely used in recent years for gene editing. The assay, named CRISPR-COVID, enables high-throughput detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) - the virus that causes COVID-19. CRISPR-COVID delivers comparable sensitivity and specificity as mNGS within as short as 40 minutes. When produced at a large scale, the material cost of a CRISPR-COVID test could be less than 70 cents, suggesting that CRISPR-COVID is a competitive alternative not only technologically but also financially.
The authors note, "In this study, we developed an isothermal, CRISPR-based diagnostic for COVID-19 with near single-copy sensitivity." and "We demonstrated a CRISPR-based assay for COVID-19 that offered shorter turn-around time and great diagnostic value, even in under-resourced settings without the need of thermal cyclers."
Peer-reviewed; Experimental study; Cells
Funding: This work was supported by the "Peak Project" Scientific Research Special Funding [DFJH2020019], the National Major Science & Technology Project for Control and Prevention of Major Infectious Diseases in China [2017ZX10103004], the Guangdong Science and Technology Department [2018B020241002] and the Guangzhou Science, Technology and Innovation Commission . The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
Citation: Hou T, Zeng W, Yang M, Chen W, Ren L, Ai J, et al. (2020) Development and evaluation of a rapid CRISPR-based diagnostic for COVID-19. PLoS Pathog 16(8): e1008705. https://doi.org/10.1371/journal.ppat.1008705
Laboratory Medicine, Provincial People's Hospital, Guangdong Academy of Medical Sciences Guangzhou, Guangdong, China
Vision Medicals Center for Infectious Diseases, Guangdong, China
Key Laboratory of Animal Gene Editing and Animal Cloning in Yunnan Province and College of Veterinary Medicine, Yunnan Agricultural University, Kunming, China
NHC Key Laboratory of Systems Biology of Pathogens and Christophe Mérieux Laboratory, IPB, CAMS-Fondation Mérieux, Institute of Pathogen Biology (IPB), Chinese Academy of Medical Sciences (CAMS) & Peking Union Medical College, Beijing, China
Department of Infectious Diseases, Huashan Hospital affiliated to Fudan University, Shanghai, China
Medical Technology School of Xuzhou Medical University, Xuzhou, China, Department of Laboratory Medicine, Affiliated Hospital of Xuzhou Medical University, Xuzhou, China
In your coverage please use this URL to provide access to the freely available paper: http://journals.plos.org/plospathogens/article?id=10.1371/journal.ppat.1008705